Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO),
announced that it has successfully launched its COVID-19 rapid
antibody test (20 minute) which tests for both IgG & IgM
antibodies, on Amazon.com's business platform. Precipio holds the
exclusive rights to distribute this product on Amazon’s platform.
The antibody test, which is manufactured in the USA by Nirmidas
Biotech, of California, was the first US-based test to receive
emergency use authorization (EUA) by the FDA for point-of-care.
The product is visible for sale on Amazon’s
website and app (click here), per the EUA approval received for the
test kit in December of 2020; however it may currently be purchased
only by qualified medical point-of-care (POC) providers. Physicians
and other medical facilities may now purchase these items directly
from Amazon, and receive them within 2 business days.
Clinical Utility of the COVID-19
Antibody Test
The purpose of this test is to identify the
presence of antibodies that have been developed after the person
has been exposed to the virus, or has been vaccinated. Antibodies
are the body’s natural biological response to an infection or
vaccination, and their development begins the body’s process of
building immunity to protect against future infections.
There are two key important benefits to knowing
if an individual has antibodies. First, individuals unknowingly
infected or those who know they were infected can determine if they
now have those antibodies. For those who are deliberating whether
to get vaccinated, this test presents a tool that can provide
additional information to make that decision. Secondly, individuals
who have been vaccinated can use the test to inform whether the
vaccination was successful and if the antibodies measured have
persisted over time.
“We are very excited to be working with our
partner Nirmidas to get this important rapid test on the largest
retail platform in the world,” said Ilan Danieli, Precipio’s Chief
Executive Officer. “We look forward to working with other retail
outlets, as well as with Nirmidas to advance this product into
at-home use, following the receipt of appropriate FDA
authorization”.
About Precipio
Precipio has built a platform designed to
eradicate the problem of misdiagnosis by harnessing the intellect,
expertise and technology developed within academic institutions and
delivering quality diagnostic information to physicians and their
patients worldwide, as well as proprietary products that serve
laboratories worldwide. Through its collaborations with world-class
academic institutions specializing in cancer research, diagnostics
and treatment such as the Yale School of Medicine, Harvard’s
Dana-Farber Cancer Institute, and the University of Pennsylvania,
Precipio offers a new standard of diagnostic accuracy enabling the
highest level of patient care. For more information, please visit
www.precipiodx.com.
Please follow us on Twitter @PrecipioDx and on
Facebook.
Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, including, among others, statements related to
the expected or potential impact of the novel coronavirus
(COVID-19) pandemic, and the related responses of the government,
consumers, and the Company, on our business, financial condition
and results of operations, and any such forward-looking statements,
whether concerning the COVID-19 pandemic or otherwise, involve
risks, assumptions and uncertainties. Except for historical
information, statements about future volumes, sales, growth, costs,
cost savings, margins, earnings, earnings per share, diluted
earnings per share, cash flows, plans, objectives, expectations,
growth or profitability are forward-looking statements based on
management’s estimates, beliefs, assumptions and projections. Words
such as “could,” “may,” “expects,” “anticipates,” “will,”
“targets,” “goals,” “projects,” “intends,” “plans,” “believes,”
“seeks,” “estimates,” “predicts,” and variations on such words, and
similar expressions that reflect our current views with respect to
future events and operational, economic and financial performance,
are intended to identify such forward-looking statements. These
forward-looking statements are only predictions, subject to risks
and uncertainties, and actual results could differ materially from
those discussed. Important factors that could affect performance
and cause results to differ materially from management’s
expectations, or could affect the Company’s ability to achieve its
strategic goals, include the uncertainties relating to the impact
of COVID-19 on the Company’s business, operations and employees and
the other factors that are described in the sections entitled “Risk
Factors” and “Management’s Discussion and Analysis” in the
Company's Annual Report on Form 10-K for the fiscal year ended
December 31, 2020, as updated from time to time in the Company’s
Securities and Exchange Commission filings.
The Company’s forward-looking statements in this
press release are based on management’s current views, beliefs,
assumptions and expectations regarding future events and speak only
as of the date of this release. The Company undertakes no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as required by the federal securities
laws.
Inquiries:
investors@precipiodx.com
+1-203-787-7888 Ext. 523
Precipio (NASDAQ:PRPO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Precipio (NASDAQ:PRPO)
Historical Stock Chart
From Apr 2023 to Apr 2024